1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
  Report
Delayed Nasdaq Copenhagen  -  10:54 2022-08-19 am EDT
37.50 DKK   -2.60%
08/18VIROGATES A/S : Half-Year Report, H1 2022
PU
08/18VIROGATES ANNOUNCES ITS HALF-YEAR REPORT FOR H1 2022 : 62% revenue growth and new EBIT guidance
AQ
08/18ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates A/S Announces Board Changes

05/30/2022 | 12:25pm EDT

ViroGates A/S announced that, as part of a renewal of the Board of Directors, Lars Kongsbak will step down as Chairman with immediate effect and that Patrik Dahlen, currently elected as Non-Executive Director, has been appointed by the Board to succeed Lars Kongsbak as Chairman of ViroGates' Board. Lars Kongsbak was appointed as Chairman of ViroGates' Board in March 2015 and has chosen to stand down as Chairman so that he can focus on his growing responsibilities as CEO of Samplix A/S. Lars will continue to serve as a Non-Executive Director on ViroGates' Board.


© S&P Capital IQ 2022
All news about VIROGATES A/S
08/18VIROGATES A/S : Half-Year Report, H1 2022
PU
08/18VIROGATES ANNOUNCES ITS HALF-YEAR RE : 62% revenue growth and new EBIT guidance
AQ
08/18ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/15VIROGATES A/S : Higher suPAR is associated with incident venous thromboembolism independen..
PU
07/15ViroGates notification of transactions by persons discharging managerial responsibiliti..
AQ
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
CI
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause..
PU
06/20Invitation to ViroGates' investor meeting
AQ
06/15ViroGates announces an offering of new shares with pre-emptive rights for existing shar..
AQ
06/15VIROGATES A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fat..
PU
More news
Financials
Sales 2021 7,66 M 1,04 M 1,04 M
Net income 2021 -17,7 M -2,41 M -2,41 M
Net cash 2021 14,9 M 2,02 M 2,02 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 129 M 17,6 M 17,6 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 14
Free-Float 50,4%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S-73.26%18
EXACT SCIENCES CORPORATION-50.56%6 809
GUARDANT HEALTH, INC.-49.65%5 148
BGI GENOMICS CO., LTD.-30.11%3 706
IOVANCE BIOTHERAPEUTICS, INC.-35.15%1 954
VERACYTE, INC.-44.61%1 633